Preview

Медицинский Совет

Расширенный поиск

АКТУАЛЬНЫЕ ПРОБЛЕМЫ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ (ПО МАТЕРИАЛАМ ЕВРОПЕЙСКОГО КОНГРЕССА КАРДИОЛОГОВ 2017 г.)

https://doi.org/10.21518/2079-701X-2017-12-82-88

Полный текст:

Аннотация

В обзорной статье на основании рекомендаций Европейского кардиологического общества и результатов клинических и регистровых исследований, озвученных на Европейском конгрессе кардиологов в 2017 г., освещены сложные вопросы, возникающие при назначении антитромботической терапии у пациентов с острым коронарным синдромом, в том числе с сопутствующей фибрилляцией предсердий; описаны перспективные стратегии управления риском ишемических и геморрагических событий; обозначены результаты исследований, оценивающих эффективность и безопасность перевода пациентов с острым коронарным синдромом с «новых» дезагрегантов на клопидогрел.

 

 

Об авторах

В. В. Кашталап
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Кемеровский государственный медицинский университет
Россия

д.м.н. 



О. Л. Барбараш
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Кемеровский государственный медицинский университет
Россия

чл.-корр. РАН, д.м.н., профессор 



Список литературы

1. Чазов Е.И. Пути снижения смертности от сердечно-сосудистых заболеваний. Терапевтический архив, 2008, 80(8): 11-16.

2. Здравоохранение в России. 2015: статистический сборник. М.: Росстат, 2015. 174 с.

3. Оганов Р.Г. Калинина А.М., Концевая А.В. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика, 2011, 4: 4-9.

4. Sanfelix-Gimeno G, Peiro S, Ferreros I, Perez-Vicente R, Librero J, Catala-Lopez F, Ortiz F, Tortosa-Nacher V. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. Journal of managed care pharmacy (JMCP), 2013, 3(19): 247-257.

5. Kostis WJ, Deng Y, Pantazopoulos JS, Moreyra AE, Kostis JB for the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes, 2010, 3: 581-589.

6. Chung SC, Gedeborg R, Nicholas O, James S, Jepsson A, Wolfe C, Heuschmann P, Wallentin L, Deanfield J, Timmis A, Jernberg T, Hemingway H. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and in the UK. Lancet, 2014, 383: 1305-1312.

7. Shah NS, Huffman MD, Ning H, Llloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999-2012. Journal of American Heart Association, 2015, 4: 1-12.

8. Smolina K, Wright FL, Rayner M, Goldacre MG. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes, 2012, 5: 532-540.

9. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal, 2017, 00: 1–66 doi: 10.1093/eurheartj/ehx393.

10. Эрлих А.Д., Барбараш О.Л., Кашталап В.В., Грацианский Н.А. Степень следования клиническим руководствам при остром коронарном синдроме без подъема ST: связь с исходами, предикторы «плохого» лечения (результаты регистра «Рекорд-3»). Комплексные проблемы сердечно-сосудистых заболеваний, 2016, 2: 75-82.

11. Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология, 2016, 56(4): 16-24.

12. Эрлих А.Д., Харченко М.С., Барбараш О.Л., Кашталап В.В., Зыков М.В., Печерина Т.Б., Шевченко И.И., Исламов Р.Р., Космачёва Е.Д., Круберг Л.К., Позднякова О.А., Горошко Н.Г., Марков В.А., Сыркина А.Г., Белокопытова Н.В., Горбунов В.В., Гагаркина Л.С., Калинкина Т.В., Зайцева О.Д., Лукьянов С.А., Тагирова Д.Р., Провоторов В.М., Грацианский Н.А. Степень приверженности к выполнению руководств по лечению острого коронарного синдрома в клинической практике российских стациона-ров и исходы в период госпитализации (дан-ные регистра «РЕКОРД-2»). Кардиология, 2013, 53(1): 14-22.

13. Седых Д.Ю., Горбунова Е.В., Зыков М.В., Кашталап В.В., Барбараш О.Л. Факторы, связанные с риском смерти и госпитализации при развитии повторного инфаркта миокарда. Креативная кардиология, 2017, 11(2): 98–108. DOI: http: //dx.doi.org/10.24022/1997-3187-2017-11-2-98-108.

14. Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии, 2013, 9(5): 494-499.

15. Bonaca MP, Bhatt D, Cohen M, Steg PG, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015 May 7, 372(19): 1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

16. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY, TRANSLATE-ACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J, 2017 Jan, 183: 62-68. doi: 10.1016/j.ahj.2016.10.006. Epub 2016 Oct 15.

17. Pollack CV Jr, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP, PLATO Investigators. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol, 2017 Jun, 40(6): 390-398. doi: 10.1002/clc.22733. Epub 2017Jun 9.

18. Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J, Goldstein P, MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel–the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care, 2015, 4: 220-229.

19. Alexopoulos D, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Angelidis C, Petousis S, Stakos D, Parissis H, Vavouranakis M, Davlouros P, Goudevenos J, Stefanadis C. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J, 2014, 167: 68-76.

20. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, Caporale R, Abrignani MG, Lupi A, Rakar S, Gulizia MM, Bovenzi FM, De Servi S, EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. Eur Heart J Acute Cardiovasc Care, 2015 4: 441-452.

21. Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, Roe MT, Bhatt DL, McNamara RL, Alexander KP. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv, 2014, 7: 585-593.

22. Bagai A, Peterson ED, Honeycutt E, Effron MB, Cohen DJ, Goodman SG, Anstrom KJ, Gupta A, Messenger JC, Wang TY. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care, 2015, 4: 499-508.

23. Biscaglia S, Campo G, Pavasini R, Tebaldi M, Tumscitz C, Ferrari R. Occurrence, causes, and outcomes after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, 27: 484-487.

24. Wang X, Xi S, Liu J, Qin L, Jing J, Yin T, Chen Y. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. Eur Heart J Suppl, 2016 May, 18(Suppl F): F19-F26. doi: 10.1093/ eurheartj/suw034. Epub 2016 May 24.

25. De Luca L, D’Ascenzo F, Musumeci G, Saia F, Parodi G, Varbella F, Marchese A, De Servi S, Berti S, Bolognese L. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. Euro Intervention, 2017 Jul 20, 13(4): 459-466. doi: 10.4244/EIJ-D-17-00092.

26. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J, 2017 May 16. doi: 10.1093/ eurheartj/ehx175.

27. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S, TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017 Aug 25. pii: S0140-6736(17)32155-4. doi: 10.1016/S0140-6736(17)32155-4.

28. Valgimigli M, Bueno H, Byrne RA, Collet J-P, et al. 2017 ESC focused update on dual antiplate-let therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2017, 0: 1-48.

29. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ‘t Hof AW, ten Berg JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013, 381(9872): 1107-1115. doi: 10.1016/S0140-6736(12) 62177-1.

30. Subherwal S, Bach R G, et al. Baseline Risk of Major Bleeding in Non–ST-Segment– Elevation Myocardial Infarction. Circulation, 2009, 119: 1873-1882.

31. Abu-Assi E, Raposeiras-Roubín S, García-Acuña J M, González-Juanatey JR. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol, 2014 Nov 26, 6(11): 1140–1148.

32. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarc tion) analysis. J Am Coll Cardiol, 2008, 51: 2028-2033.

33. Mehta SR et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol, 2012, 60: 2490–2499.

34. Schmitt J et al Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J, 2009, 30: 1038–1045.

35. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography. PLoS ONE, 2011, 6(9): e24964. doi: 10.1371/journal.pone.0024964.

36. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology, 2014, 11: 639-654. doi: 10.1038/ nrcardio.2014.118.

37. Bang CN, Gislason GH, Greve AM, Bang C A, et al. New-Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89 703 Patients With Long-Term Follow-Up: A Nationwide Study. J Am Heart Assoc, 2014, 3: e000382 doi: 10.1161/JAHA.113.000382.

38. Rene AG, Généreux P, Ezekowitz M, et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am. J. Cardiol., 2014, 113: 236-242.

39. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002, 347: 969-974.

40. Lamberts M et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention. Circulation, 2012. 126. 1185-1193.

41. Potpara TS, Lane DA, Lip GYH. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace, 2015, 17(4): 507-508.

42. Lip G et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal, 2014, doi: 10.1093/eurheartj/ehu298.

43. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361(12): 1139-51.

44. Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol, 2016 Oct, 39(10): 555-564. doi: 10.1002/ clc.22572. Epub 2016 Aug 26.

45. Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017 Jan 24, 135(4): 323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Erratum in: Circulation. 2017 Mar 21, 135(12): e789.


Просмотров: 198


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)